Nu-Med Plus Inc.
0.0300+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · NUMD · USD
Key Stats
Market Cap
2.51MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Nu-Med Plus posted a narrower net loss of $11,665 for Q2 ended June 30, 2025, down 32.5% y/y from $17,287, while YTD losses shrank to $31,598 from $39,112, or 19.2% y/y, thanks to trimmed operating expenses like dues and subscriptions. No revenue yet, as the early-stage medtech firm hones nitric oxide delivery tech amid funding hunts. Cash dipped to $863 from $2,373 at year-start, with operating cash burn at $1,510 YTD; a $100,000 related-party note payable looms due December 31, 2025. Post-quarter, officers chipped in $14,000 for ops. Stockholders' deficit widened to $246,694. Funding remains the crux.
10-Q
Q1 FY2025 results
Nu-Med Plus posted a narrower net loss of $19,933 for Q1 FY2025 ended March 31, 2025, down from $21,826 a year earlier, thanks to operating expenses dropping 9.2% y/y to $18,700 (derived) on lower professional and consulting fees. Interest expense ticked down slightly to $1,233, while revenue stayed at zero amid suspended product development. Cash held steady at $2,373, with zero net cash used in operations, but liabilities climbed to $240,202, deepening the working capital deficit to $235,029. No free cash flow or non-GAAP metrics disclosed in the 10-Q. Funding needs loom large at $1.2M over the next year. Development stalled without capital. Cybersecurity threats pose ongoing risks to operations.
10-K
FY2024 results
NU-MED Plus reported no revenue for FY2024 ended December 31, 2024, with operating expenses dropping to $63,331 from $120,526 in 2023, yielding a net loss of $68,345 versus $125,526 the prior year; the narrower loss stemmed from slashed stock-based compensation, rent, and professional fees, but quarterly breakdowns remain undisclosed in the 10-K. Development of nitric oxide delivery prototypes halted amid funding shortages, leaving cash at a mere $2,373 against $224,469 in liabilities, sufficient for just two more months without fresh capital. No dividends, buybacks, or capex materialized. The company eyes mergers and patent filings, yet auditors flag substantial going-concern doubts. We lack funding to advance. Regulatory delays loom large, potentially stalling quarterly progress indefinitely.
10-Q
Q3 FY2024 results
Nu-Med Plus reported no revenue for Q3 FY2024 ended September 30, 2024, with operating expenses up 15% y/y to $17,417 from $15,146, driven by higher professional fees and filing costs, while rent expense dropped to zero. This yielded an operating loss of $17,417, widening 15% y/y, and a net loss of $18,677 after $1,260 interest, compared to $16,406 last year. For the nine months, operating expenses fell 17% y/y to $54,037, trimming the net loss to $57,790 from $68,930, thanks to lower legal and rent outlays. Cash dwindled to $4,041 from $6,806 year-end, with net operating cash use at $2,765 versus $62,107 prior year; a $100,000 note payable persists alongside $111,329 in payables. The planned merger with YourSpace America collapsed in October 2024, forcing a leadership shuffle. No free cash flow disclosed in the 10-Q. Funding remains the core risk.
8-K
YourSpace acquisition terminated
Nu-Med Plus's planned acquisition of YourSpace America unraveled on October 28, 2024, after YourSpace failed to deliver 2023 audited financials and terminated the share exchange agreement originally announced in April. Newly appointed CEO Russ Colvin resigned immediately, while Chairman William Hayde stepped in as interim President and CEO. No stock issuance or control shift occurred. Deal collapse preserves status quo.
EMED
Electromedical Technologies, In
0.00+0.00
HSDT
Solana Company
6.78+0.17
MDNC
MEDINOTEC INC
5.00+0.00
MODD
Modular Medical, Inc.
0.52-0.01
NAOV
NanoVibronix, Inc.
5.57-0.32
NUWE
Nuwellis, Inc.
3.05-0.05
NVNO
enVVeno Medical Corporation
0.72+0.00
NXL
Nexalin Technology, Inc.
1.55+0.07
PMI
Picard Medical, Inc.
3.28-0.77
SNWV
SANUWAVE Health, Inc.
30.44-0.60